Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/143373
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer’s disease |
Autor: | Sogorb-Esteve, Aitana CSIC; García-Ayllón, María-Salud CSIC ORCID; Fortea, Juan; Sánchez-Valle, Raquel; Lleó, Alberto; Molinuevo, José Luis; Sáez-Valero, Javier CSIC ORCID | Palabras clave: | Presenilin-1 Cerebrospinal fluid Biomarkers Pre-symptomatic Autosomal dominant Alzheimer’s disease Down syndrome Mild-cognitive impairment |
Fecha de publicación: | 29-sep-2016 | Editor: | Edufma | Citación: | Molecular Neurodegeneration 11: 66 (2016) | Resumen: | [Background] Presenilin-1 (PS1), the active component of the intramembrane γ-secretase complex, can be detected as soluble heteromeric aggregates in cerebrospinal fluid (CSF). The aim of this study was to examine the different soluble PS1 complexes in the lumbar CSF (CSF-PS1) of individuals with Alzheimer’s disease (AD), particularly in both symptomatic and asymptomatic genetically determined AD, in order to evaluate their potential as early biomarkers. [Methods] Western blotting, differential centrifugation and co-immunoprecipitation served to determine and characterize CSF-PS1 complexes. We also monitored the assembly of soluble PS1 into complexes in a cell model, and the participation of Aβ in the dynamics and robustness of the stable PS1 complexes. [Results] There was an age-dependent increase in CSF-PS1 levels in cognitively normal controls, the different complexes represented in similar proportions. The total levels of CSF-PS1, and in particular the proportion of the stable 100–150 kDa complexes, increased in subjects with autosomal dominant AD that carried PSEN1 mutations (eight symptomatic and six asymptomatic ADAD) and in Down syndrome individuals (ten demented and ten non-demented DS), compared with age-matched controls (n = 23), even prior to the appearance of symptoms of dementia. The proportion of stable CSF-PS1 complexes also increased in sporadic AD (n = 13) and mild-cognitive impaired subjects (n = 12), relative to age-matched controls (n = 17). Co-immunoprecipitation demonstrated the association of Aβ oligomers with soluble PS1 complexes, particularly the stable complexes. [Conclusions] Our data suggest that CSF-PS1 complexes may be useful as an early biomarker for AD, reflecting the pathology at asymptomatic state. |
Versión del editor: | https://doi.org/10.1186/s13024-016-0131-2 | URI: | http://hdl.handle.net/10261/143373 | DOI: | 10.1186/s13024-016-0131-2 | ISSN: | 1750-1326 |
Aparece en las colecciones: | (IN) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
cerebrospinal_fluid_Sogord.pdf | 1,85 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
5
checked on 17-mar-2024
SCOPUSTM
Citations
7
checked on 12-mar-2024
WEB OF SCIENCETM
Citations
8
checked on 28-feb-2024
Page view(s)
278
checked on 18-mar-2024
Download(s)
204
checked on 18-mar-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.